Literature DB >> 9109781

Topical corticosteroid treatment of anosmia associated with nasal and sinus disease.

A E Mott1, W S Cain, D Lafreniere, G Leonard, J F Gent, M E Frank.   

Abstract

OBJECTIVE: To establish the efficacy of topical corticosteroid nasal spray treatment of severe olfactory loss associated with severe nasal and sinus disease.
DESIGN: Efficacy before and after open-label trial of topical corticosteroid nasal spray used exclusively in the head-down-forward position.
SETTING: Taste and smell clinic of a university teaching hospital and research facility. PATIENTS: Taste and smell clinic patients with anosmia or severe hyposmia associated with paranasal sinus disease and nasal polyposis including 39 of 45 patients recruited from 1988 to 1994 who completed the topical corticosteroid treatment course and returned for subsequent testing. INTERVENTION: At least 8 weeks of treatment with flunisolide (Nasalide), 2 sprays in each nostril twice a day, with concurrent antibiotic treatment of any bacterial infection. MAIN OUTCOME MEASURES: Subjective olfactory symptoms, objective olfactory function tests, and otolaryngological evaluation (including endoscopic examination).
RESULTS: Olfactory scores significantly improved following treatment (P < .001); signs of nasal and sinus disease significantly decreased (P < .001); and 26 (66%) of the patients reported a subjective improvement in their sense of smell.
CONCLUSION: Topical corticosteroid nasal spray administered in a head-down-forward position is an effective treatment of severe olfactory loss associated with severe nasal and sinus disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9109781     DOI: 10.1001/archotol.1997.01900040009001

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  15 in total

1.  [Treatment of olfactory disorders].

Authors:  T Hummel; B A Stuck
Journal:  HNO       Date:  2010-07       Impact factor: 1.284

Review 2.  [Olfactory dysfunction due to nasal sinus disease. Causes, consequences, epidemiology, and therapy].

Authors:  T Hummel; K B Hüttenbrink
Journal:  HNO       Date:  2005-05       Impact factor: 1.284

3.  Drug carrier nanoparticles that penetrate human chronic rhinosinusitis mucus.

Authors:  Samuel K Lai; Jung Soo Suk; Amanda Pace; Ying-Ying Wang; Ming Yang; Olcay Mert; Jeane Chen; Jean Kim; Justin Hanes
Journal:  Biomaterials       Date:  2011-06-12       Impact factor: 12.479

4.  Does oral prednisolone increase the efficacy of subsequent nasal steroids in treating nasal polyposis?

Authors:  Virat Kirtsreesakul; Krongthong Wongsritrang; Suwalee Ruttanaphol
Journal:  Am J Rhinol Allergy       Date:  2012 Nov-Dec       Impact factor: 2.467

Review 5.  Olfaction in Chronic Rhinosinusitis.

Authors:  Philippe Rombaux; C Huart; P Levie; C Cingi; T Hummel
Journal:  Curr Allergy Asthma Rep       Date:  2016-05       Impact factor: 4.806

Review 6.  Olfaction and anosmia in rhinosinusitis.

Authors:  Pamela Dalton
Journal:  Curr Allergy Asthma Rep       Date:  2004-05       Impact factor: 4.806

Review 7.  [Olfactory dysfunctions. Epidemiology and therapy in Germany, Austria and Switzerland].

Authors:  M Damm; A Temmel; A Welge-Lüssen; H E Eckel; M-P Kreft; J P Klussmann; H Gudziol; K-B Hüttenbrink; T Hummel
Journal:  HNO       Date:  2004-02       Impact factor: 1.284

8.  Olfactory impairment in adults.

Authors:  Carla R Schubert; Karen J Cruickshanks; Claire Murphy; Guan-Hua Huang; Barbara E K Klein; Ronald Klein; F Javier Nieto; James S Pankow; Ted S Tweed
Journal:  Ann N Y Acad Sci       Date:  2009-07       Impact factor: 5.691

9.  Re-establishment of olfactory and taste functions.

Authors:  Antje Welge-Lüssen
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2005-09-28

10.  Hidden consequences of olfactory dysfunction: a patient report series.

Authors:  Andreas Keller; Dolores Malaspina
Journal:  BMC Ear Nose Throat Disord       Date:  2013-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.